As Rho signalling inhibits a vital component of EDH, KCa2.3 channels located on the endothelium, our data support the rationale for treating endothelial dysfunction and related disorders by targeting Rho signalling. This evidence concerns the gene KCNN3 and endothelial dysfunction.